Osr Holdings Inc (OSRH)

$0.55 -0.04 (-6.29%)
Market Cap 14.11M
Revenue (ttm) 2.91M
Net Income (ttm) -2.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.03
Volume 903,900
Avg Vol 864,844
Day's Range N/A - N/A
Shares Out 25.67M
Stochastic %K 69%
Beta 0.59
Analysts Strong Buy
Price Target N/A

Company Profile

OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Switzerland, and South Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma that is in phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is...

Industry: Biotechnology
Sector: Healthcare
Phone: 425 635 7700
Address:
10900 NE 4th Street, Suite 2300, Bellevue, United States
KeepItRealistic
KeepItRealistic Apr. 5 at 5:51 PM
$OSRH Once Institutions come in Manipulators won’t stand a chance
0 · Reply
Genesys01
Genesys01 Apr. 5 at 3:17 PM
$OSRH This manipulations are the reason for it that the Nasdaq is disfunctional now. The SEC doesnt care below 100 million MCap. In Europe (e.g. Frankfurt) such manipulations are criminal and in Europe the are behind such actors. In Europe they plan a new europe-wide stock exchange which has the power to attract more companies than the Nasdaq does. The only way to survive for the Nasdaq will be a honest and fair market. SEC should wake up, this is their job.
0 · Reply
Roland115
Roland115 Apr. 5 at 1:55 PM
$OSRH I would honestly completely ban any kind of stock lending.. short selling, creating synthetic stocks that don't even exist... ASK-BID manipulation and all those criminal scams that are seen every day... with the clear intention of suppressing the stock price... let them sell their own stocks like we do...✅ we buy stocks and sell them... and those scumbags should do the same... any idiot can borrow stocks... that's why they are rightly called financial criminals...
0 · Reply
Genesys01
Genesys01 Apr. 5 at 11:57 AM
$OSRH Unfortunately the market manipulators (MMs) are knowing this: In the last days the amount of shares available for lending has been increased from 550k to 1.1 million shares. As I have seen there are just approx 1.5 million shares available for lending at all. Means if company sends good messages, the short sellers will see it as an invitation for the next round of manipulation. This will just stop when OSRH generates more revenue but this door is nearby open.
0 · Reply
rodyar
rodyar Apr. 4 at 5:39 PM
$OSRH just took substantial position last week so hoping for big things from company
1 · Reply
Roland115
Roland115 Apr. 4 at 3:06 PM
$OSRH I hope that society will soon send a very surprising message to financial criminals and send them right back where these scumbags belong...???,,, to the bottom of the hole,😛
0 · Reply
KeepItRealistic
KeepItRealistic Apr. 4 at 12:59 PM
$OSRH DD is your friend 👇 what is BCME goals in its funding strategy for Vaximm ? BCM Europe AG (BCME) is a Switzerland-based life sciences investment entity that functions primarily as a development-stage biotech financier and licensing intermediary. Core Goals and Business Model Its main objective in deals like the VXM01 transaction is to act as a bridge between early-stage biotech assets (often from smaller companies or subsidiaries) and larger pharmaceutical partners. Specifically: • Bridge development and de-risk assets: BCME takes on assets like VXM01, funds or supports further clinical development (via dedicated investment vehicles/funds), and advances them to a point where they can be out-licensed to a major pharma company for global commercialization. Read On 👇 (limited in text size posts)
0 · Reply
KeepItRealistic
KeepItRealistic Apr. 4 at 12:34 PM
$OSRH $815 million binding term sheet details https://www.sec.gov/Archives/edgar/data/1840425/000121390026039691/ea028505701ex10-1.htm It’s a binding term sheet, with Execution targeted for late April 2026 Read on 👇
0 · Reply
KeepItRealistic
KeepItRealistic Apr. 4 at 12:22 AM
$OSRH just a tiny slice of that Market would do wonders to our stock price ! “Global CGM market: ~USD 5–11 billion recently, heading toward USD 10–30+ billion by 2030–2034 (CAGRs ~7–13%).”
1 · Reply
KeepItRealistic
KeepItRealistic Apr. 3 at 9:04 PM
$OSRH If a FUNDING Company can accept $15 million in funding at $10 a share on top of the $815M funding “dilution free” for trials and commercialism of the companies Vaximm product. The funder is clearly expecting the share price to go higher than $10 !!! Common sense 101
2 · Reply
Latest News on OSRH
OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026

Mar 30, 2026, 9:00 AM EDT - 6 days ago

OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026

Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target

Mar 27, 2026, 9:00 AM EDT - 9 days ago

Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target

OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level

Mar 23, 2026, 8:30 AM EDT - 13 days ago

OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level

Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities

Mar 19, 2026, 8:55 AM EDT - 17 days ago

Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities

OSR Holdings, Inc. Granted 180-Day Nasdaq Extension; Reaffirms Strategic Momentum

Mar 5, 2026, 9:30 AM EST - 4 weeks ago

OSR Holdings, Inc. Granted 180-Day Nasdaq Extension; Reaffirms Strategic Momentum

CEO Statement to Shareholders

Feb 2, 2026, 9:50 AM EST - 2 months ago

CEO Statement to Shareholders

OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries

Jan 27, 2026, 8:30 AM EST - 2 months ago

OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries

Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch

Jan 22, 2026, 9:55 AM EST - 2 months ago

Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch

Vaximm Appoints Sébastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform

Jan 16, 2026, 9:20 AM EST - 2 months ago

Vaximm Appoints Sébastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform

Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones

Jan 12, 2026, 8:05 AM EST - 2 months ago

Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones

Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings

Dec 19, 2025, 11:50 AM EST - 3 months ago

Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings

Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target Following Major Licensing Agreement

Dec 4, 2025, 3:19 PM EST - 4 months ago

Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target Following Major Licensing Agreement

Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three Months

Dec 2, 2025, 9:53 AM EST - 4 months ago

Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three Months

OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025

Dec 1, 2025, 3:01 PM EST - 4 months ago

OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025

Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones

Nov 21, 2025, 9:20 AM EST - 4 months ago

Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones

OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion

Nov 14, 2025, 11:10 AM EST - 5 months ago

OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion

OSR Holdings Announces Woori IO's Noninvasive Glucose Monitor Demonstrates High Accuracy and Precision in Company-Sponsored Pilot Study

Nov 6, 2025, 8:30 AM EST - 5 months ago

OSR Holdings Announces Woori IO's Noninvasive Glucose Monitor Demonstrates High Accuracy and Precision in Company-Sponsored Pilot Study

Emerging Growth Research Initiates Coverage on OSR Holdings, Inc. with a Buy-Emerging Rating and $10.00 Price Target

Oct 20, 2025, 11:39 AM EDT - 5 months ago

Emerging Growth Research Initiates Coverage on OSR Holdings, Inc. with a Buy-Emerging Rating and $10.00 Price Target

OSR Holdings Signs Definitive Agreement to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring with Potential to Transform Diabetes Care

Oct 14, 2025, 8:30 AM EDT - 6 months ago

OSR Holdings Signs Definitive Agreement to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring with Potential to Transform Diabetes Care

OSR Holdings Receives Nasdaq Minimum Bid Price Deficiency Notice; Company Highlights Unusual Trading Activity

Sep 9, 2025, 5:30 PM EDT - 7 months ago

OSR Holdings Receives Nasdaq Minimum Bid Price Deficiency Notice; Company Highlights Unusual Trading Activity

OSR Holdings to Host Virtual Investor Event Providing Key Corporate Updates and Strategic Direction on August 6, 2025

Aug 1, 2025, 1:29 PM EDT - 8 months ago

OSR Holdings to Host Virtual Investor Event Providing Key Corporate Updates and Strategic Direction on August 6, 2025

OSR Holdings Provides Transparency Update on Equity Financing Instruments

Jul 31, 2025, 12:45 PM EDT - 8 months ago

OSR Holdings Provides Transparency Update on Equity Financing Instruments

OSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange Structure

Jul 30, 2025, 4:10 PM EDT - 8 months ago

OSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange Structure

OSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring Technology

Jul 24, 2025, 7:30 AM EDT - 9 months ago

OSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring Technology

OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company

Jul 15, 2025, 7:30 AM EDT - 9 months ago

OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company

OSR Holdings Announces Strategic Roadmap for Tokenization Under Reg D Framework in Partnership with BCM Europe AG

Jul 9, 2025, 7:58 AM EDT - 9 months ago

OSR Holdings Announces Strategic Roadmap for Tokenization Under Reg D Framework in Partnership with BCM Europe AG

OSR Holdings, BCM Europe, and Taekwondo Cooperative Announce Strategic MOU to Launch Blockchain-Based OSRH Token

May 22, 2025, 7:36 AM EDT - 11 months ago

OSR Holdings, BCM Europe, and Taekwondo Cooperative Announce Strategic MOU to Launch Blockchain-Based OSRH Token

Darnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics

May 2, 2025, 7:30 AM EDT - 1 year ago

Darnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics

Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology

Apr 9, 2025, 7:54 AM EDT - 1 year ago

Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology

OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies

Apr 3, 2025, 7:30 AM EDT - 1 year ago

OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies

Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma

Mar 26, 2025, 7:16 AM EDT - 1 year ago

Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma

OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer

Mar 25, 2025, 7:00 AM EDT - 1 year ago

OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer

OSR Holdings, Inc. and OSR Holdings Co., Ltd. Announce Completion of Business Combination

Feb 14, 2025, 6:10 PM EST - 1 year ago

OSR Holdings, Inc. and OSR Holdings Co., Ltd. Announce Completion of Business Combination

KeepItRealistic
KeepItRealistic Apr. 5 at 5:51 PM
$OSRH Once Institutions come in Manipulators won’t stand a chance
0 · Reply
Genesys01
Genesys01 Apr. 5 at 3:17 PM
$OSRH This manipulations are the reason for it that the Nasdaq is disfunctional now. The SEC doesnt care below 100 million MCap. In Europe (e.g. Frankfurt) such manipulations are criminal and in Europe the are behind such actors. In Europe they plan a new europe-wide stock exchange which has the power to attract more companies than the Nasdaq does. The only way to survive for the Nasdaq will be a honest and fair market. SEC should wake up, this is their job.
0 · Reply
Roland115
Roland115 Apr. 5 at 1:55 PM
$OSRH I would honestly completely ban any kind of stock lending.. short selling, creating synthetic stocks that don't even exist... ASK-BID manipulation and all those criminal scams that are seen every day... with the clear intention of suppressing the stock price... let them sell their own stocks like we do...✅ we buy stocks and sell them... and those scumbags should do the same... any idiot can borrow stocks... that's why they are rightly called financial criminals...
0 · Reply
Genesys01
Genesys01 Apr. 5 at 11:57 AM
$OSRH Unfortunately the market manipulators (MMs) are knowing this: In the last days the amount of shares available for lending has been increased from 550k to 1.1 million shares. As I have seen there are just approx 1.5 million shares available for lending at all. Means if company sends good messages, the short sellers will see it as an invitation for the next round of manipulation. This will just stop when OSRH generates more revenue but this door is nearby open.
0 · Reply
rodyar
rodyar Apr. 4 at 5:39 PM
$OSRH just took substantial position last week so hoping for big things from company
1 · Reply
Roland115
Roland115 Apr. 4 at 3:06 PM
$OSRH I hope that society will soon send a very surprising message to financial criminals and send them right back where these scumbags belong...???,,, to the bottom of the hole,😛
0 · Reply
KeepItRealistic
KeepItRealistic Apr. 4 at 12:59 PM
$OSRH DD is your friend 👇 what is BCME goals in its funding strategy for Vaximm ? BCM Europe AG (BCME) is a Switzerland-based life sciences investment entity that functions primarily as a development-stage biotech financier and licensing intermediary. Core Goals and Business Model Its main objective in deals like the VXM01 transaction is to act as a bridge between early-stage biotech assets (often from smaller companies or subsidiaries) and larger pharmaceutical partners. Specifically: • Bridge development and de-risk assets: BCME takes on assets like VXM01, funds or supports further clinical development (via dedicated investment vehicles/funds), and advances them to a point where they can be out-licensed to a major pharma company for global commercialization. Read On 👇 (limited in text size posts)
0 · Reply
KeepItRealistic
KeepItRealistic Apr. 4 at 12:34 PM
$OSRH $815 million binding term sheet details https://www.sec.gov/Archives/edgar/data/1840425/000121390026039691/ea028505701ex10-1.htm It’s a binding term sheet, with Execution targeted for late April 2026 Read on 👇
0 · Reply
KeepItRealistic
KeepItRealistic Apr. 4 at 12:22 AM
$OSRH just a tiny slice of that Market would do wonders to our stock price ! “Global CGM market: ~USD 5–11 billion recently, heading toward USD 10–30+ billion by 2030–2034 (CAGRs ~7–13%).”
1 · Reply
KeepItRealistic
KeepItRealistic Apr. 3 at 9:04 PM
$OSRH If a FUNDING Company can accept $15 million in funding at $10 a share on top of the $815M funding “dilution free” for trials and commercialism of the companies Vaximm product. The funder is clearly expecting the share price to go higher than $10 !!! Common sense 101
2 · Reply
KeepItRealistic
KeepItRealistic Apr. 3 at 8:39 PM
$OSRH Company keeps on making changes to reward us And nitwits selling their shares for bread crumbs 🤷🏻‍♂️ One thing I have learnt is that there are alot of 🧠 ☠️ sheep investing in small caps that do zero DD Can’t wait for institutional investors to Come in and take over this float 🎯 minimum 👇 funder at $10
0 · Reply
focafoca99
focafoca99 Apr. 3 at 8:26 PM
$OSRH reworked the VXM01 license structure with BCM Europe so the parent company becomes a direct counterparty and main recipient of milestone and royalty payments.
0 · Reply
Howie3
Howie3 Apr. 3 at 5:58 PM
$IXHL Your not alone - These Bio Companies get Pumped with Promises of Fortune and most do not succeed - I have been down the road with 3 of them already - Alls they do is reverse split and then barely hang on to keep from de listing - I left IXHL the day the reverse split was announced - Had $5500 left over - I put it all in $OSRH - That bought me 11,000 shares - Hope that one works - If you have questions as to why I chose $OSRH feel free to ask or do just do your own re search - Good Luck
1 · Reply
Roland115
Roland115 Apr. 3 at 5:54 PM
$OSRH Do I understand correctly that we are still waiting for PR... that it is definitely signed with BCME Europe,,?
1 · Reply
Roland115
Roland115 Apr. 3 at 3:59 PM
$OSRH What more could you ask for here... the company management is fast, and responsive✅ All companies should take the example of the OSRH...✅
2 · Reply
KeepItRealistic
KeepItRealistic Apr. 3 at 1:55 PM
$OSRH official SEC filing “OSR Holdings, Inc. shall retain an option to issue up to $15,000,000 of OSRH common stock to the BCME Fund at a price of $10.00 per share, exercisable at OSRH’s sole discretion no earlier than six (6) months following execution of the definitive Global License Agreement.” https://www.sec.gov/Archives/edgar/data/1840425/000121390026039691/ea028505701ex10-1.htm
1 · Reply
Annet_why_net
Annet_why_net Apr. 3 at 1:03 PM
$OSRH Can you believe this? This is the first time I've seen a company not only reply to an investor's email but actually issue an official SEC filing to correct a discrepancy! They updated the Equity Option price back to $10.00. Marry me, man!
2 · Reply
KeepItRealistic
KeepItRealistic Apr. 3 at 12:35 PM
$OSRH that was fast ! https://www.sec.gov/ix?doc=/Archives/edgar/data/0001840425/000121390026039691/ea0285057-8ka1_osr.htm ❤️ this company !
0 · Reply
Spiderman1979
Spiderman1979 Apr. 3 at 12:24 PM
$OSRH I think they are showing us the writing on the wall.
1 · Reply
Roland115
Roland115 Apr. 3 at 12:21 PM
$OSRH ✅✅OSR Holdings filed an amended Form 8-K to replace Exhibit 10.1 with a corrected version of its Global License Agreement for VXM01 dated March 23, 2026. Amendment corrected clerical errors in agreement, including stated per-share price. Filing left all other disclosures in original April 2, 2026 report unchanged.✅✅
0 · Reply
KeepItRealistic
KeepItRealistic Apr. 3 at 11:55 AM
$OSRH I emailed the company IR and they confirmed its an error and will be corrected 👇
1 · Reply
Frog007
Frog007 Apr. 3 at 5:43 AM
$OSRH another chinese SCAM. Every body run
2 · Reply